Secreted miR-210-3p as non-invasive biomarker in clear cell renal cell carcinoma

V. Petrozza, A. L. Pastore, G. Palleschi, C. Tito, N. Porta, S. Ricci, C. Marigliano, M. Costantini, G. Simone, A. Di Carlo, M. Gallucci, A. Carbone, F. Fazi

Research output: Contribution to journalArticlepeer-review


The most common subtype of renal cell carcinoma (RCC) is clear cell RCC (ccRCC). It accounts for 70-80% of all renal malignancies representing the third most common urological cancer after prostate and bladder cancer. The identification of non-invasive biomarkers for the diagnosis and responsiveness to therapy of ccRCC may represent a relevant step-forward in ccRCC management. The aim of this study is to evaluate whether specific miRNAs deregulated in ccRCC tissues present altered levels also in urine specimens. To this end we first assessed that miR-21-5p, miR-210-3p and miR-221-3p resulted upregulated in ccRCC fresh frozen tissues compared to matched normal counterparts. Next, we evidenced that miR-210-3p resulted significantly up-regulated in 38 urine specimens collected from two independent cohorts of ccRCC patients at the time of surgery compared to healthy donors samples. Of note, miR-210-3p levels resulted significantly reduced in follow-up samples. These results point to miR-210-3p as a potential non-invasive biomarker useful not only for diagnosis but also for the assessment of complete resection or response to treatment in ccRCC management.
Original languageEnglish
Pages (from-to)69551-69558
Issue number41
Publication statusPublished - Jun 13 2017


  • biomarkers
  • ccRCC
  • miR-210-3p
  • microRNAs
  • urine specimens


Dive into the research topics of 'Secreted miR-210-3p as non-invasive biomarker in clear cell renal cell carcinoma'. Together they form a unique fingerprint.

Cite this